2026 AASLD | 范建高教授团队:发现MASLD相关肾损伤的脂质通路
2026 AASLD会议上,范建高教授团队证实LPC‑ATX‑LPA轴失调参与代谢功能障碍相关脂肪性肝病(MASLD)相关肾损伤。在小鼠模型中,使用ATX抑制剂PF‑8380或LPA受体拮抗剂Ki16425治疗后,尿白蛋白/肌酐比值显著降低。该通路为MASLD合并肾损伤防治提供了潜在干预靶点。
11分钟前 肝胆相照平台 肝胆相照平台 发表于上海
AASLD2026 范建高团队研究证实,LPC‑ATX‑LPA 轴失调参与 MASLD 相关肾损伤;抑制该通路可减轻肾脏损害,为 MASLD 合并肾损伤提供新靶点。
2026年11月5日-9日,全球肝病领域顶级学术盛会-The Liver Meeting 2026 (AASLD 2026)在美国•丹佛召开。本届大会汇聚来自世界各地的肝病临床专家与基础研究学者,围绕病毒性肝炎、代谢功能障碍相关脂肪性肝病、肝硬化及其并发症、肝癌、肝移植和肝病基础研究等领域,集中展示前沿研究成果与临床诊疗新进展。
会上,上海交通大学医学院附属新华医院范建高教授团队一项围绕“LPC‑ATX‑LPA 轴调控异常参与MASLD相关肾损伤”的研究精彩亮相大会。该研究证实,MASLD进展过程中LPC‑ATX‑LPA信号轴显著紊乱,是介导MASLD相关肾损伤的重要机制;靶向抑制ATX‑LPA通路,可有效减轻MASLD相关肾脏损害,为MASLD合并肾损伤的防治提供全新靶点。肝胆相照平台特整理该项研究核心内容,供广大临床同道参考学习。
摘要编号:1352
LPC-ATX-LPA轴失调促进了MASLD相关的肾损伤
背景
代谢功能障碍相关脂肪性肝病(MASLD)是最常见的慢性肝病,已成为一个全球性健康问题。不断积累的临床证据表明,MASLD与慢性肾脏病(CKD)风险增加独立相关。本研究旨在探讨溶血磷脂酰胆碱(LPC)-自分泌运动因子(ATX)-溶血磷脂酸(LPA)轴在MASLD相关肾损伤中的作用。
方法
本研究采用小鼠模型和人群队列,研究MASLD相关肾损伤及伴随的循环代谢变化。雄性C57BL/6J小鼠分别喂养高脂、高胆固醇和高果糖饮食(HFCFD)12、18或24周,以模拟MASLD的时间进展。在各疾病阶段,对小鼠进行全面表型分析,包括血清生化指标、血清胱抑素C定量、肝脏脂质测定、尿白蛋白测定和尿氢过氧化物定量测定。对肝脏和肾脏组织切片进行组织学分析,并进一步通过透射电子显微镜观察肾脏超微结构变化。
同时,纳入患者并根据活检确定的MASLD分期进行分层,采集血清样本进行脂质组学分析,并定量检测血清ATX和LPA水平。研究使用了两种药理学抑制剂:ATX抑制剂PF-8380和LPA受体拮抗剂Ki16425。HFCFD喂养18周后,小鼠每日接受PF-8380、Ki16425或溶剂的腹腔注射,持续6周。
结果
随着饮食诱导的MASLD进展,小鼠肾损伤逐渐加重。不同疾病阶段小鼠的血清胱抑素C、尿白蛋白、尿白蛋白/肌酐比值(UACR)和尿氢过氧化物/肌酐比值均显著升高。组织学分析显示,肾小球横截面积增大。
透射电子显微镜进一步显示,肾小球足细胞足突局灶性融合、肾小球基底膜增厚,以及肾小管上皮细胞线粒体异常。随着疾病严重程度增加,这些结构和功能改变均进一步加重。对活检确诊MASLD患者进行基于LC-MS的非靶向血清脂质组学分析发现,LPC是变化最明显的脂质类别;随着MASLD进展,LPC 18:1和LPC 18:2逐渐降低。血清ATX和LPA水平也随MASLD进展而升高。与接受溶剂处理的HFCFD小鼠相比,接受PF-8380和Ki16425处理的小鼠UACR显著降低。
结论
研究结果表明,LPC-ATX-LPA轴在MASLD进展过程中明显失调。药理学抑制ATX-LPA信号减轻了MASLD相关肾损伤。
英文原文
DYSREGULATION OF THE LPC-ATX-LPA AXIS CONTRIBUTES TO MASLD-ASSOCIATED KIDNEY INJURY
作者:Mengyuan Wu¹, Qin Pan², Jiangao Fan¹
1 Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease and has emerged as a global health problem. Accumulating clinical evidence has demonstrated that MASLD is independently associated with an increased risk of chronic kidney disease (CKD). This study aimed to explore the role of the lysophosphatidylcholine (LPC)-autotaxin (ATX)-lysophosphatidic acid (LPA) axis in MASLD-associated kidney injury.
Methods
A murine model and a human cohort were used to investigate MASLD-associated kidney injury and accompanying circulating metabolic alterations. Male C57BL/6J mice were fed a high-fat, high-cholesterol, and high-fructose diet (HFCFD) for 12, 18, or 24 weeks to recapitulate the temporal progression of MASLD. At each disease stage, mice underwent comprehensive phenotyping, including serum biochemistry, serum cystatin C quantification, hepatic lipid measurement, urinary albumin measurement, and urinary hydrogen peroxide quantification. Histological analyses were performed using liver and kidney tissue ps, and renal ultrastructural changes were further examined by transmission electron microscopy. In parallel, patients were enrolled and stratified according to biopsy-defined MASLD stage, and serum samples were collected for lipidomic profiling. Serum ATX and LPA levels were quantified. Two pharmacological inhibitors were used: the ATX inhibitor PF-8380 and the LPA receptor antagonist Ki16425. After 18 weeks of HFCFD feeding, mice received daily intraperitoneal injections of PF-8380, Ki16425, or vehicle for 6 weeks.
Results
With the progression of diet-induced MASLD, mice developed progressively worsening kidney injury. Serum cystatin C, urinary albumin, urinary albumin-to-creatinine ratio (UACR), and urinary hydrogen peroxide-to-creatinine ratio were significantly increased across disease stages. Histological analysis showed enlargement of glomerular cross-pal area. Transmission electron microscopy further revealed segmental podocyte foot process effacement, glomerular basement membrane thickening, and mitochondrial abnormalities in renal tubular epithelial cells. These structural and functional alterations worsened with advancing disease severity. LC-MS-based untargeted serum lipidomic profiling of patients with biopsy-confirmed MASLD revealed that LPCs were the most prominently altered lipid class, with LPC 18:1 and LPC 18:2 progressively decreasing as MASLD advanced. Serum ATX and LPA levels also increased with MASLD progression. Compared with vehicle-treated HFCFD mice, UACR was significantly reduced in PF-8380- and Ki16425-treated mice.
Conclusion
Our findings indicate that the LPC-ATX-LPA axis is markedly dysregulated during MASLD progression. Pharmacological inhibition of ATX-LPA signaling attenuated MASLD-associated kidney injury.
版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
来源:梅斯医学·临床资讯 · news.medsci.cn
